Vanguard Personalized Indexing Management’s Jyong Biotech MENS Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio MENS Stock Details MENS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.9K	Buy	+13,927	New	+$34.1K	﹤0.01%	2096

Other funds holding MENS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Personalized Indexing Management's MENS Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Jyong Biotech (MENS) in Q1 2026: 13,927 shares worth $29.9K. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings.

17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

Vanguard Personalized Indexing Management held 13,927 shares of Jyong Biotech worth $29.9K as of Q1 2026.
Jyong Biotech was a new Vanguard Personalized Indexing Management position in Q1 2026.
Jyong Biotech made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2096 holding.
17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.